Rongrong Zheng
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Study on the risk factors for colorectal polyp recurrence: a cross-sectional retrospective cohort study.
Journal: Frontiers in medicine
Published: December 30, 2024
Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies.
Journal: Cancer immunology, immunotherapy : CII
Published: December 02, 2024
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 09, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 02, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
Journal: Nature medicine
Published: March 29, 2024
Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Journal: Clinical and translational medicine
Published: November 27, 2023
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Journal: Signal transduction and targeted therapy
Published: September 29, 2023
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.
Journal: Nature communications
Published: April 18, 2022
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 08, 2021
Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Journal: Annals of translational medicine
Published: January 25, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026